These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16757022)

  • 1. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
    Steinhauser I; Spänkuch B; Strebhardt K; Langer K
    Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
    Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
    Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles.
    Kouchakzadeh H; Shojaosadati SA; Tahmasebi F; Shokri F
    Int J Pharm; 2013 Apr; 447(1-2):62-9. PubMed ID: 23454849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
    Dinauer N; Balthasar S; Weber C; Kreuter J; Langer K; von Briesen H
    Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.
    Steinhauser I; Langer K; Strebhardt K; Spänkuch B
    J Drug Target; 2009 Sep; 17(8):627-37. PubMed ID: 19591537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.
    Taheri A; Dinarvand R; Atyabi F; Ghahremani MH; Ostad SN
    Eur J Pharm Sci; 2012 Sep; 47(2):331-40. PubMed ID: 22771547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
    Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
    Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
    Sun B; Ranganathan B; Feng SS
    Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.
    Chiu SJ; Ueno NT; Lee RJ
    J Control Release; 2004 Jun; 97(2):357-69. PubMed ID: 15196762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
    Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
    J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
    Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
    Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells.
    Ulbrich K; Michaelis M; Rothweiler F; Knobloch T; Sithisarn P; Cinatl J; Kreuter J
    Int J Pharm; 2011 Mar; 406(1-2):128-34. PubMed ID: 21185364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
    Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A
    J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.
    Wartlick H; Michaelis K; Balthasar S; Strebhardt K; Kreuter J; Langer K
    J Drug Target; 2004; 12(7):461-71. PubMed ID: 15621671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
    Spänkuch B; Steinhauser I; Wartlick H; Kurunci-Csacsko E; Strebhardt KI; Langer K
    Neoplasia; 2008 Mar; 10(3):223-34. PubMed ID: 18320067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.